Two Phase III studies tested PARP inhibitors for metastatic recurrent HER2-negative germline BRCA-positive breast cancer, OlympiAD, comparing Olaparib alone with standard physicians’ choice of chemotherapy, showed a significant prolongation of PFS with a median of 7.0 months versus 4.2 months [93]; another trial, EMBRACA, compared talazoparib monotherapy with standard physicians’ choice of chemotherapy, and also showed significantly prolonged PFS with a median of 8.6 months versus 5.6 months [94]. Here, ERBB2 is linked to breast carcinoma.